Activation of the receptor for advanced glycation end products induces nuclear inhibitor of protein phosphatase-1 suppression

Kidney International

Volumn 86, Issue 1, 2014, Pages 103-117

  Liebisch, Marita ^a   Bondeva, Tzvetanka ^a   Franke, Sybille ^a   Daniel, Christoph ^b   Amann, Kerstin ^b   Wolf, Gunter ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

AGEs; DN; NIPP1; PP1; RAGE

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUCLEAR INHIBITOR OF PROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 1; PODOCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCTS-BOVINE SERUM ALBUMIN; BOVINE SERUM ALBUMIN; CDKN1B PROTEIN, MOUSE; LYSINE; MESSENGER RNA; N(6)-CARBOXYMETHYLLYSINE; PHOSPHOPROTEIN PHOSPHATASE; PPP1R8 PROTEIN, HUMAN; PROTEIN PHOSPHATASE INHIBITOR-1; RIBONUCLEASE; RNA BINDING PROTEIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; ENZYME ACTIVITY; GENE ACTIVATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; KIDNEY HYPERTROPHY; MOUSE; NONHUMAN; NUCLEAR INHIBITOR OF PROTEIN PHOSPHATASE 1 GENE; NUCLEOTIDE SEQUENCE; PODOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CELL CULTURE; CELL CYCLE CHECKPOINT; CELL ENLARGEMENT; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENETICS; METABOLISM; NECROSIS; PATHOLOGY;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ANIMALS; APOPTOSIS; CASE-CONTROL STUDIES; CELL CYCLE CHECKPOINTS; CELL ENLARGEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIABETIC NEPHROPATHIES; DOWN-REGULATION; ENDORIBONUCLEASES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSINE; MICE; NECROSIS; NF-KAPPA B; PHOSPHOPROTEIN PHOSPHATASES; PODOCYTES; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SERUM ALBUMIN, BOVINE;

EID: 84903774695     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.3     Document Type: Article

References (69)

1. Reddy GR, Kotlyarevska K, Ransom RF et al. The podocyte and diabetes mellitus: Is the podocyte the key to the origins of DN? Curr Opin Nephrol Hypertens 2008; 17: 32-36.
2. Stieger N, Worthmann K, Schiffer M. The role of metabolic and haemodynamic factors in podocyte injury in diabetes. Diabetes Metab Res Rev 2011; 27: 207-215.
3. Welsh GI, Coward RJ. Podocytes, glucose and insulin. Curr Opin Nephrol Hypertens 2010; 19: 379-384.
4. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in DN. Diabetes 2005; 54: 1626-1634. (Pubitemid 40770751)
5. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348. (Pubitemid 27053474)
6. Bohlender JM, Franke S, Stein G et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289: F645-F659. (Pubitemid 41324185)
7. Miyata T, Wada Y, Cai Z et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51: 1170-1181. (Pubitemid 27186543)
8. Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 14987-14997.
9. Bierhaus A, Humpert PM, Morcos M et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83: 876-886. (Pubitemid 41598688)
10. Bierhaus A, Humpert PM, Stern DM et al. Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci 2005; 1043: 676-680. (Pubitemid 41123959)
11. Ruster C, Bondeva T, Franke S et al. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 2008; 23: 2179-2191. (Pubitemid 351957612)
12. Wendt T, Tanji N, Guo J et al. Glucose, glycation, and RAGE: Implications for amplification of cellular dysfunction in DN. J Am Soc Nephrol 2003; 14: 1383-1395. (Pubitemid 36514678)
13. Wendt TM, Tanji N, Guo J et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of DN. Am J Pathol 2003; 162: 1123-1137. (Pubitemid 36350658)
14. Bierhaus A, Wolf J, Andrassy M et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003; 100: 1920-1925. (Pubitemid 36254549)
15. Haslbeck KM, Schleicher E, Bierhaus A et al. The AGE/RAGE/NF-kB pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 2005; 113: 288-291. (Pubitemid 40868185)
16. Wolf G, Jablonski K, Schroeder R et al. Angiotensin II-induced hypertrophy of proximal tubular cells requires p27Kip1. Kidney Int 2003; 64: 71-81. (Pubitemid 36714159)
17. Xu ZG, Yoo TH, Ryu DR et al. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int 2005; 67: 944-952.
18. Beullens M, Van Eynde A, Stalmans W et al. The isolation of novel inhibitory polypeptides of protein phosphatase 1 from bovine thymus nuclei. J Biol Chem 1992; 267: 16538-16544.
19. Beullens M, Van Eynde A, Vulsteke V et al. Molecular determinants of nuclear protein phosphatase-1 regulation by NIPP-1. J Biol Chem 1999; 274: 14053-14061.
20. Beullens M, Vulsteke V, Van Eynde A et al. The C-Terminus of NIPP1 (nuclear inhibitor of protein phosphatase-1) contains a novel binding site for protein phosphatase-1 that is controlled by tyrosine phosphorylation and RNA binding. Biochem J 2000; 352(Pt 3): 651-658. (Pubitemid 32015019)
21. Van Eynde A, Wera S, Beullens M et al. Molecular cloning of NIPP-1, a nuclear inhibitor of protein phosphatase-1, reveals homology with polypeptides involved in RNA processing. J Biol Chem 1995; 270: 28068-28074.
22. Eto M, Senba S, Morita F et al. Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: Its specific localization in smooth muscle. FEBS Lett 1997; 410: 356-360. (Pubitemid 27304096)
23. Ceulemans H, Bollen M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev 2004; 84: 1-39. (Pubitemid 38049874)
24. Lesage B, Beullens M, Nuytten M et al. Interactor-mediated nuclear translocation and retention of protein phosphatase-1. J Biol Chem 2004; 279: 55978-55984. (Pubitemid 40066605)
25. Beullens M, Bollen M. The protein phosphatase-1 regulator NIPP1 is also a splicing factor involved in a late step of spliceosome assembly. J Biol Chem 2002; 277: 19855-19860. (Pubitemid 34967504)
26. Jin Q, Beullens M, Jagiello I et al. Mapping of the RNA-binding and endoribonuclease domains of NIPP1, a nuclear targeting subunit of protein phosphatase 1. Biochem J 1999; 342: 13-19. (Pubitemid 29410843)
27. Jagiello I, Van Eynde A, Vulsteke V et al. Nuclear and subnuclear targeting sequences of the protein phosphatase-1 regulator NIPP1. J Cell Sci 2000; 113(Part 21): 3761-3768.
28. Beullens M, Van Eynde A, Bollen M et al. Inactivation of nuclear inhibitory polypeptides of protein phosphatase-1 (NIPP-1) by protein kinase A. J Biol Chem 1993; 268: 13172-13177. (Pubitemid 23307734)
29. Van Eynde A, Beullens M, Stalmans W et al. Full activation of a nuclear species of protein phosphatase-1 by phosphorylation with protein kinase A and casein kinase-2. Biochem J 1994; 297: 447-449. (Pubitemid 24056094)
30. Vulsteke V, Beullens M, Waelkens E et al. Properties and phosphorylation sites of baculovirus-expressed nuclear inhibitor of protein phosphatase-1 (NIPP-1). J Biol Chem 1997; 272: 32972-32978. (Pubitemid 28023635)
31. Nelson DA, Krucher NA, Ludlow JW. High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein. J Biol Chem 1997; 272: 4528-4535. (Pubitemid 27078533)
32. Runnegar MT, Kong S, Berndt N. Protein phosphatase inhibition and in vivo hepatotoxicity of microcystins. Am J Physiol 1993; 265: G224-G230. (Pubitemid 23273625)
33. Berndt N, Dohadwala M, Liu CW. Constitutively active protein phosphatase 1alpha causes Rb-dependent G1 arrest in human cancer cells. Curr Biol 1997; 7: 375-386. (Pubitemid 27274791)
34. Henley SA, Dick FA. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div 2012; 7: 10.
35. Bondeva T, Ruster C, Franke S et al. Advanced glycation end-products suppress neuropilin-1 expression in podocytes. Kidney Int 2009; 75: 605-616.
36. Boudrez A, Beullens M, Waelkens E et al. Phosphorylation-dependent interaction between the splicing factors SAP155 and NIPP1. J Biol Chem 2002; 277: 31834-31841. (Pubitemid 34968990)
37. Wolf G, Schanze A, Stahl RA et al. p27Kip1 Knockout mice are protected from DN: Evidence for p27Kip1 haplotype insufficiency. Kidney Int 2005; 68: 1583-1589. (Pubitemid 43169903)
38. Cohen MP, Clements RS, Hud E et al. Evolution of renal function abnormalities in the db/db mouse that parallels the development of human DN. Exp Nephrol 1996; 4: 166-171. (Pubitemid 26162138)
39. Kilhovd BK, Giardino I, Torjesen PA et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 2003; 52: 163-167. (Pubitemid 36388837)
40. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-1031. (Pubitemid 28417334)
41. Wautier JL, Zoukourian C, Chappey O et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238-243.
42. Goova MT, Li J, Kislinger T et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159: 513-525. (Pubitemid 32751082)
43. Schmidt AM, Hasu M, Popov D et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 1994; 91: 8807-8811.
44. Busch M, Franke S, Wolf G et al. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis 2006; 48: 571-579. (Pubitemid 44425379)
45. Schiekofer S, Andrassy M, Chen J et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003; 52: 621-633. (Pubitemid 36323567)
46. Schleicher E. The significance of the Maillard reaction in human physiology. Z Ernahrungswiss 1991; 30: 18-28.
47. Fu MX, Wells-Knecht KJ, Blackledge JA et al. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43: 676-683.
48. Bierhaus A, Nawroth PP. Posttranslational modification of lipoproteins-A fatal attraction in metabolic disease? J Alzheimers Dis 2005; 7: 315-317.
49. Xue J, Rai V, Singer D et al. Advanced glycation end product recognition by the receptor for AGEs. Structure 2011; 19: 722-732.
50. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011; 1243: 88-102.
51. Tanji N, Markowitz GS, Fu C et al. Expression of advanced glycation end products and their cellular receptor RAGE in DN and nondiabetic renal disease. J Am Soc Nephrol 2000; 11: 1656-1666.
52. Mundel P, Reiser J. New aspects of podocyte cell biology. Kidney Blood Press Res 1997; 20: 173-176. (Pubitemid 27390004)
53. Trinkle-Mulcahy L, Ajuh P, Prescott A et al. Nuclear organisation of NIPP1, a regulatory subunit of protein phosphatase 1 that associates with pre-mRNA splicing factors. J Cell Sci 1999; 112(Part 2): 157-168. (Pubitemid 29078350)
54. Jandeleit-Dahm K, Watson A, Soro-Paavonen A. The AGE/RAGE axis in diabetes-Accelerated atherosclerosis. Clin Exp Pharmacol Physiol 2008; 35: 329-334. (Pubitemid 351260012)
55. Lindsey JB, Cipollone F, Abdullah SM et al. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): Cardiovascular implications. Diabetes Vasc Dis Res 2009; 6: 7-14.
56. Boudrez A, Beullens M, Groenen P et al. NIPP1-mediated interaction of protein phosphatase-1 with CDC5L, a regulator of pre-mRNA splicing and mitotic entry. J Biol Chem 2000; 275: 25411-25417.
57. Bollen M. Combinatorial control of protein phosphatase-1. Trends Biochem Sci 2001; 26: 426-431. (Pubitemid 32607484)
58. Boudrez A, Evens K, Beullens M et al. Identification of MYPT1 and NIPP1 as subunits of protein phosphatase 1 in rat liver cytosol. FEBS Lett 1999; 455: 175-178. (Pubitemid 29322805)
59. Qian J, Lesage B, Beullens M et al. PP1/Repo-man dephosphorylates mitotic histone H3 at T3 and regulates chromosomal aurora B targeting. Curr Biol 2011; 21: 766-773.
60. Lesage B, Qian J, Bollen M. Spindle checkpoint silencing: PP1 tips the balance. Curr Biol 2011; 21: R898-R903.
61. Saurin AT, van der Waal MS, Medema RH et al. Aurora B potentiates Mps1 activation to ensure rapid checkpoint establishment at the onset of mitosis. Nat Commun 2011; 2: 316.
62. Maldonado M, Kapoor TM. Moving right along: How PP1 helps clear the checkpoint. Dev Cell 2011; 20: 733-734.
63. Wolf G, Reinking R, Zahner G et al. Erk 1,2 phosphorylates p27Kip1: Functional evidence for a role in high glucose-induced hypertrophy of mesangial cells. Diabetologia 2003; 46: 1090-1099. (Pubitemid 37041239)
64. Wolf G, Schroeder R, Zahner G et al. High glucose-induced hypertrophy of mesangial cells requires p27Kip1, an inhibitor of cyclin-dependent kinases. Am J Pathol 2001; 158: 1091-1100. (Pubitemid 32221801)
65. Franke S, Sommer M, Ruster C et al. Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells. Arthritis Res Ther 2009; 11: R136.
66. Devangelio E, Santilli F, Formoso G et al. Soluble RAGE in type 2 diabetes: Association with oxidative stress. Free Radic Biol Med 2007; 43: 511-518. (Pubitemid 47058227)
67. Mundel P, Reiser J, Zuniga Mejia Borja A et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258. (Pubitemid 27452369)
68. Busch M, Franke S, Ruster C et al. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010; 40: 742-755.
69. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408. (Pubitemid 34164012)